Liquidia (NASDAQ:LQDA) Stock: Insider Jason Adair Sells 7,301 Shares

Liquidia Corporation (NASDAQ:LQDA) insider Jason Adair sold 7,301 shares of Liquidia stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $28.48, for a total transaction of $207,932.48. Following the transaction, the insider directly owned 177,957 shares in the company, valued at $5,068,215.36. The trade was a 3.94% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jason Adair also recently made the following trade(s):

• On Friday, August 21st, Jason Adair sold 73,631 shares of Liquidia stock. The shares were sold at an average price of $69.09, for a total transaction of $5,087,165.79.
• On Monday, July 27th, Jason Adair sold 688 shares of Liquidia stock. The shares were sold at an average price of $87.53, for a total transaction of $60,220.64.

Liquidia Stock Up 26.6%

Shares of NASDAQ:LQDA opened at $33.94 on Thursday. The company has a 50 day moving average price of $62.30 and a two-hundred day moving average price of $61.74. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31. The company has a market capitalization of $3.04 billion, a PE ratio of 24.77 and a beta of 0.61. Liquidia Corporation has a 52 week low of $21.94 and a 52 week high of $93.61.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). The firm had revenue of $171.68 million for the quarter, compared to the consensus estimate of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The company’s revenue for the quarter was up 1842.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.49) earnings per share. Analysts forecast that Liquidia Corporation will post 2.05 earnings per share for the current year.

Institutional Investors Weigh In On Liquidia

A number of institutional investors have recently added to or reduced their stakes in LQDA. WINTON GROUP Ltd acquired a new stake in Liquidia in the second quarter valued at $335,000. Arizona State Retirement System grew its position in shares of Liquidia by 5.4% during the 2nd quarter. Arizona State Retirement System now owns 17,627 shares of the company’s stock worth $1,405,000 after buying an additional 900 shares during the period. Nykredit A S bought a new stake in Liquidia in the second quarter valued at $177,000. Corient Private Wealth LP acquired a new position in Liquidia during the 2nd quarter worth approximately $758,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Liquidia during the second quarter worth approximately $1,236,000. 64.54% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have commented on LQDA. HC Wainwright dropped their target price on shares of Liquidia from $130.00 to $58.00 and set a “buy” rating on the stock in a report on Friday, October 2nd. Citigroup reissued a “neutral” rating on shares of Liquidia in a research report on Thursday, October 1st. BTIG Research upgraded Liquidia from a “neutral” rating to a “buy” rating and set a $70.00 price target for the company in a report on Wednesday. Wedbush set a $58.00 price target on Liquidia in a report on Friday, October 2nd. Finally, Bank of America upped their target price on Liquidia from $79.00 to $92.00 and gave the company a “neutral” rating in a research report on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Liquidia has a consensus rating of “Hold” and an average target price of $77.31.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: The settlement allows Liquidia to continue commercializing YUTREPIA for pulmonary arterial hypertension (PAH) without interruption, removing a major source of legal and commercial uncertainty. Liquidia settlement announcement
• Positive Sentiment: Preliminary third-quarter YUTREPIA sales reached $222.7 million, contributing to $396.1 million in cash and equivalents. Management said it expects ongoing sales and existing cash to fund settlement obligations and clinical programs without additional financing. RTTNews settlement report
• Positive Sentiment: Analyst sentiment improved following the agreement. BTIG upgraded LQDA from “neutral” to “buy” with a $70 price target, while Lifesci Capital raised its rating to “outperform” and set a $59 target. Needham maintained “buy” but lowered its target to $58.
• Positive Sentiment: Trading activity reflected strong investor interest, with call-option volume more than doubling its average level.
• Neutral Sentiment: Liquidia agreed to pay United Therapeutics a net $380.7 million, including $175 million within 30 business days, $145.4 million in 2027 installments and $60.3 million tied to the antitrust litigation. The payments resolve the disputes but will significantly draw down cash.
• Negative Sentiment: The company will not appeal the patent ruling and is removing the PH-ILD indication from YUTREPIA’s label. It also ended promotion of Treprostinil Injection, narrowing potential revenue opportunities. Zacks settlement analysis
• Negative Sentiment: Multiple executives and insiders sold shares under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested awards. Because the sales were planned and left executives with substantial holdings, they are a limited standalone signal, but broader insider activity remains heavily weighted toward selling.

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).